Author:
Treon Steven P.,Merlini Giampaolo
Reference198 articles.
1. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s macroglobulinemia. Semin Oncol. 2003;30:110–5.
2. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
3. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni Jr JF. Waldenström’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer. 1998;82:1078–81.
4. Hanzis C, Ojha RP, Hunter Z, Manning R, Lewicki M, Brodsky P, et al. Associated malignancies in patients with Waldenström’s macroglobulinemia and their Kin. Clin Lymphoma Myeloma Leuk. 2011;11:88–92.
5. Varettoni M, Tedesci A, Arcaini L, et al. Risk of second cancers in Waldenstrom macroglobulinemia. Ann Oncol. 2012;23:411–5.